Med. praxi. 2019;16(2):90-96 | DOI: 10.36290/med.2019.014

Hypertension and atrial fibrillation: a complex problem requiring one comprehensive solution

doc. MUDr. Robert Holaj, CSc., MBA
Centrum pro hypertenzi, III. interní klinika – klinika endokrinologie a metabolismu VFN a 1. LF UK, Praha

Hypertension has a major impact on the pathogenesis, management, and prognosis of atrial fibrillation. Common consequences of hypertension, such as left ventricular hypertrophy, kidney dysfunction, cardiovascular, and cerebrovascular disorders, are recognized risk factors for AF occurrence and development of its complications. Hypertension is very common in AF patients, and evidence points toward a significant contribution of high blood pressure to AF incidence. Patients with hypertension have 1.7-fold higher risk of developing AF than normotensive individuals, and 1 in 6 cases of AF has been attributed to hypertension. Given the high incidence of AF in hypertension, one may even argue that AF is yet another manifestation of the hypertensive target organ damage.

Keywords: arterial hypertension, atrial fibrillation, new oral anticoagulants, stroke, warfarin

Published: April 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Holaj R. Hypertension and atrial fibrillation: a complex problem requiring one comprehensive solution. Med. praxi. 2019;16(2):90-96. doi: 10.36290/med.2019.014.
Download citation

References

  1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke; a journal of cerebral circulation 1991; 22: 983-988. Go to original source... Go to PubMed...
  2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952. Go to original source... Go to PubMed...
  3. Hamer ME, Blumenthal JA, McCarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. The American journal of cardiology 1994; 74: 826-829. Go to original source... Go to PubMed...
  4. Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 2010; 7: 433-437. Go to original source... Go to PubMed...
  5. Post WS, Larson MG, Levy D. Hemodynamic predictors of incident hypertension. The Framingham Heart Study. Hypertension 1994; 24: 585-590. Go to original source... Go to PubMed...
  6. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. The American journal of cardiology 1998; 82: 2N-9N. Go to original source... Go to PubMed...
  7. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England journal of medicine 2008; 358: 1547-1559. Go to original source... Go to PubMed...
  8. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218-223. Go to original source... Go to PubMed...
  9. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. Journal of the American College of Cardiology 2005; 45: 712-719. Go to original source... Go to PubMed...
  10. Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296: 1242-1248. Go to original source... Go to PubMed...
  11. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation 2009; 119: 2146-2152. Go to original source... Go to PubMed...
  12. Grundvold I, Skretteberg PT, Liestol K, et al. Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension 2012; 59: 198-204. Go to original source... Go to PubMed...
  13. Domenech M, Berruezo A, Molina I, Mont L, Coca A. Nighttime ambulatory blood pressure is associated with atrial remodelling and neurohormonal activation in patients with idiopathic atrial fibrillation. Revista espanola de cardiologia 2013; 66: 458-463. Go to original source... Go to PubMed...
  14. Okin PM, Hille DA, Larstorp AC, et al. Effect of lower on-treatment systolic blood pressure on the risk of atrial fibrillation in hypertensive patients. Hypertension 2015; 66: 368-373. Go to original source... Go to PubMed...
  15. Dzeshka MS, Shahid F, Shantsila A, Lip GYH. Hypertension and Atrial Fibrillation: An Intimate Association of Epidemiology, Pathophysiology, and Outcomes. Am J Hypertens 2017; 30: 733-755. Go to original source... Go to PubMed...
  16. Nagarakanti R, Wallentin L, Noack H, et al. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). The American journal of cardiology 2015; 116: 1204-1209. Go to original source... Go to PubMed...
  17. Rao MP, Halvorsen S, Wojdyla D, et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Journal of the American Heart Association 2015; 4. Go to original source... Go to PubMed...
  18. Vemulapalli S, Hellkamp AS, Jones WS, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. American heart journal 2016; 178: 74-84. Go to original source... Go to PubMed...
  19. Pokorney SD, Piccini JP, Stevens SR, et al. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association 2016; 5: e002197. Go to original source... Go to PubMed...
  20. Dzeshka MS, Brown RA, Capodanno D, Lip GY. Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting. Interv Cardiol Clin 2017; 6: 91-117. Go to original source... Go to PubMed...
  21. Vidal-Petiot E, Ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016; 388: 2142-2152. Go to original source... Go to PubMed...
  22. Mitchell GF. Arterial stiffness and hypertension. Hypertension 2014; 64: 13-18. Go to original source... Go to PubMed...
  23. Patel N, O'Neal WT, Whalen SP, Soliman EZ. Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass. Ann Noninvasive Electrocardiol 2017; 22: 1-5. Go to original source... Go to PubMed...
  24. Rahman F, Yin X, Larson MG, et al. Trajectories of Risk Factors and Risk of New-Onset Atrial Fibrillation in the Framingham Heart Study. Hypertension 2016; 68: 597-605. Go to original source... Go to PubMed...
  25. Gepner AD, Tedla Y, Colangelo LA, et al. Progression of Carotid Arterial Stiffness With Treatment of Hypertension Over 10 Years: The Multi-Ethnic Study of Atherosclerosis. Hypertension 2017; 69: 87-95. Go to original source... Go to PubMed...
  26. Barron AJ, Hughes AD, Sharp A, et al. Long-Term Antihypertensive Treatment Fails to Improve E/e' Despite Regression of Left Ventricular Mass: An Anglo-Scandinavian Cardiac Outcomes Trial Substudy. Hypertension 2014; 63: 252-258. Go to original source... Go to PubMed...
  27. Welsh P, Poulter NR, Chang CL, Sever PS, Sattar N, Investigators A. The Value of N-Terminal Pro-B-Type Natriuretic Peptide in Determining Antihypertensive Benefit: Observations From the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2014; 63: 507-513. Go to original source... Go to PubMed...
  28. Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E. Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications. Journal of the American College of Cardiology 2015; 66: 943-959. Go to original source... Go to PubMed...
  29. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Archives of internal medicine 1994; 154: 1449-1457.
  30. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. European heart journal 2012; 33: 1500-1510. Go to original source... Go to PubMed...
  31. Lip GY, Frison L, Grind M, Invetigators S. Effect of hypertension on anticoagulated patients with atrial fibrillation. European heart journal 2007; 28: 752-759. Go to original source... Go to PubMed...
  32. Katsanos AH, Filippatou A, Manios E, et al. Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials. Hypertension 2017; 69: 171-179. Go to original source... Go to PubMed...
  33. Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy: the Bleeding with Antithrombotic Therapy (BAT) Study. Stroke; a journal of cerebral circulation 2010; 41: 1440-1444. Go to original source... Go to PubMed...
  34. Buglioni A, Cannone V, Cataliotti A, et al. Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension 2015; 65: 45-53. Go to original source... Go to PubMed...
  35. Catena C, Verheyen N, Pilz S, et al. Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Naive Patients With Hypertension: Tissue-Doppler Imaging Study. Hypertension 2015; 65: 1231-1237. Go to original source... Go to PubMed...
  36. Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. Hypertension 2017; 69: 545-550. Go to original source... Go to PubMed...
  37. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068. Go to original source... Go to PubMed...
  38. Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791. Go to original source... Go to PubMed...
  39. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. The New England journal of medicine 2014; 370: 1383-1392. Go to original source... Go to PubMed...
  40. Neefs J, van den Berg NW, Limpens J, et al. Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. Int J Cardiol 2017; 231: 155-161. Go to original source... Go to PubMed...
  41. Shantsila E, Haynes R, Calvert M, et al. IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. BMJ Open 2016; 6: e012241. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.